Related Experiment Video
Updated: May 6, 2026
11:17
Stability and Structure of Bat Major Histocompatibility Complex Class I with Heterologous β2-Microglobulin
Published on: March 10, 2021
4.8K
Decipher β2-microglobulin: gain- or loss-of-function (a mini-review)
Shean-Jaw Chiou1, Chang-Han Chen
1Department of Biochemistry, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Taiwan.
Medical Science Monitor Basic Research
|October 23, 2013
Summary
Beta-2 microglobulin (β2M) is crucial for MHC class I stability and antigen presentation. Its cytoplasmic localization in advanced oral cancers suggests a role in tumorigenesis and offers a potential therapeutic target.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Beta-2 microglobulin (β2M) stabilizes the MHC class I complex, essential for antigen presentation to CD8+ T cells.
- Loss-of-function in β2M can help cancer cells evade immune surveillance.
- Elevated β2M levels correlate with tumor status in various cancers, indicating prognostic potential.
Purpose of the Study:
- To investigate the role of β2M in cancer, particularly its localization and potential as a therapeutic target.
- To explore the mechanism of β2M-mediated tumorigenesis in oral cavity squamous cell carcinoma (OCSCC).
Main Methods:
- Analysis of β2M localization in normal oral mucosa versus advanced OCSCC.
- Review of β2M's function in MHC class I complex stability and antigen presentation.
- Consideration of anti-β2M monoclonal antibodies as a therapeutic strategy.
Main Results:
- β2M accumulates in the cytoplasm of advanced OCSCC, unlike its plasma membrane localization in normal cells.
- This cytoplasmic accumulation may precede β2M-derived intracellular signaling.
- Anti-β2M antibodies induce apoptosis in malignant cells, suggesting therapeutic utility.
Conclusions:
- The translocation of β2M from the cell surface to the cytoplasm in advanced tumors is a key finding.
- This intracellular accumulation and signaling may drive tumorigenesis.
- Targeting β2M presents a novel therapeutic avenue for managing malignancies.
Related Concept Videos
02:28Leaky Scanning
4.5K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
4.5K
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
190
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
190
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
01:15Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
160
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160